CSTL241220P30000
- 1.09
- -0.06-5.22%
Castle Biosciences Newsroom
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx-Melanoma Test, Contributing to Personalized Management of Patients With Melanoma
Here's Why Agios Stock Plummeted More Than 20% on Monday
Insider Sale: Director at $CSTL (CSTL) Sells 4,669 Shares
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
JANX Stock Hits Record High on Prostate Cancer Study Data
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
Corcept Shares Rise More Than 60% in Three Months: Here's Why
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Castle Biosciences, Inc.'s (NASDAQ:CSTL) Business Is Trailing The Industry But Its Shares Aren't
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx-Melanoma and MyPath Melanoma at the American Society of Dermatopathology 61st Annual Meeting
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why
Castle Biosciences Surpasses 25,000 Test Reports Delivered for Its TissueCypher Barrett's Esophagus Test
Castle Biosciences Is Maintained at Sector Outperform by Scotiabank
Scotiabank Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $44